First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

In interim analysis (n=296), patients on lorlatinib, a third-generation ALK inhibitor, had significantly longer progression-free survival than those who received crizotinib (78% vs. 38% alive without .disease progression at 12 months; HR 0.28; 95% CI, 0.19 to 0.41; p<0.001)

Source:

New England Journal of Medicine